Efficacy of zoledronic acid in older prostate cancer patients undergoing androgen deprivation therapy

Ippei Kojima; Yushi Naito; Akiyuki Yamamoto; Yasuhiro Terashima; Norie Sho; Jun Nagayama; Yurika Okada; Tatsuya Nagai

추천

검색

자료유형: 학술저널

저자정보: Ippei Kojima (Department of Urology Toyohashi Municipal Hospital Toyohashi Aichi Japan) Yushi Naito (Department of Urology Toyohashi Municipal Hospital Toyohashi Aichi Japan) Akiyuki Yamamoto (Department of Urology Toyohashi Municipal Hospital Toyohashi Aichi Japan) Yasuhiro Terashima (Department of Urology Toyohashi Municipal Hospital Toyohashi Aichi Japan) Norie Sho (Department of Urology Toyohashi Municipal Hospital Toyohashi Aichi Japan) Jun Nagayama (Department of Urology Toyohashi Municipal Hospital Toyohashi Aichi Japan) Yurika Okada (Department of Urology Toyohashi Municipal Hospital Toyohashi Aichi Japan) Tatsuya Nagai (Department of Urology Toyohashi Municipal Hospital Toyohashi Aichi Japan)

저널정보: 대한골다공증학회 Osteoporosis and Sarcopenia Osteoporosis and Sarcopenia Vol.5 No.4

발행연도: 2019.1

수록면: 128 - 131 (4page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Objectives: The purpose of this study is to evaluate the efficacy of annual zoledronic acid treatment in Japanese patients with nonmetastatic prostate cancer during androgen deprivation therapy (ADT). Methods: This is a single institution 12-month study. Between 2016 and 2019, patients aged 70 years or older on ADT for nonmetastatic prostate cancer had bone mineral density (BMD) measured and 10-year probability of fracture calculated using fracture risk assessment tool (FRAX). Patients who showed osteopenia or had a 10-year hip fracture risk 3% or a 10-year probability of major osteoporotic fracture 20% were offered treatment with zoledronic acid 5 mg intravenously (ZA group). The patients who did not receive treatment were set as the control group. Lumbar and hip BMD were measured 6 and 12 months after treatment in the ZA group and 12 months after baseline in the control group. The yearly BMD change of both groups was compared. Results: The mean ages of the ZA group (n ¼ 26) and control group (n ¼ 12) were 80.5 ± 9.1 and 76.1 ± 6.7 years, respectively. In the ZA group, lumbar and hip BMD changes at 12 months were þ2.1% and þ0.8%, respectively. In the control group, lumbar and hip BMD changes were 0.9% and 4.9%, respectively. There were statistically significant differences between the 2 groups in BMD percent changes (P < 0.05). Conclusions: Without intervention, BMD tends to continue to decrease during ADT. Our findings suggest that administration of zoledronic acid enables maintenance of BMD in the older adults.

#Androgen deprivation therapy #Bone mineral density #Osteoporosis #Prostate cancer #Zoledronic acid

참고문헌 (19)

참고문헌 신청

Onozawa M / 2014 / Recent trends in the initial therapy for newly diagnosed prostate cancer in Japan / Jpn J Clin Oncol 44:969~981

Bergstrom I / 2004 / Changes in bone mineral density differ between gonadotrophin-releasing hormone analogue-and surgically castrated men with prostate cancerea prospective, controlled, parallel-group study / Scand J Urol Nephrol 38:148~152

Berruti A / 2002 / Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy / J Urol 167:2361~2367

Daniell HW / 2000 / Progressive osteoporosis during androgen deprivation therapy for prostate cancer / J Urol 163:181~186

Cheung AS / 2014 / Muscle and bone effects of androgen deprivation therapy: current and emerging therapies / Endocr Relat Cancer 21:R371~R394

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!